CMChemtai Mungo

Chemtai Mungo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chemtai Mungo has a total of 141 co-authors. Here are the top co-authors by number of shared publications:

  • Jackton Omoto

    Department of Obstetrics and Gynecology, Maseno University School of Medicine, Kisumu, Kenya

    11 shared publications
  • Lisa Rahangdale

    Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill, Chapel Hill, NC, USA

    10 shared publications
  • Craig R. Cohen

    Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA

    7 shared publications
  • Katherine Sorgi

    Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

    6 shared publications
  • Mercy Rop

    Center for Microbiology Research Kenya Medical Research Institute Kisumu Kenya

    5 shared publications
  • Cirilus Ogollah Osongo

    Kenya Medical Research Institute Kisumu Kenya

    4 shared publications

Latest Publications

  • Open Access

    Persistent human papillomavirus after thermal ablation in Malawian women with and without HIV: Implications for risk-based cervical cancer prevention in low- and middle-income countries

    by Jessica Gingles, Yating Zou, Lameck Chinula, Jennifer H. Tang, Ivy Kaliati, Tawonga Mkochi, Lizzie Msowoya, Charity Nakanga, Friday Saidi, Jennifer S. Smith, et al.

    Background: Persistent high-risk human papillomavirus (hrHPV) infection can lead to cervical precancer, with women living with HIV (WLWH) at increased risk due to impaired immune clearance. Thermal ablation (TA) is a low-cost treatment for precancerous lesions, but data on hrHPV persistence after TA among WLWH are limited. Objectives: To evaluate overall and channel-specific hrHPV persistence 12 months after TA among women in Lilongwe, Malawi. Design: Cross-sectional analysis of Malawian women who received TA during and after the PEER trial (prevention of cervical cancer through two HPV-based screen-and-treat implementation models in Malawi). Methods: We analyzed 495 hrHPV-positive women (113 WLWH, 382 without HIV) treated with TA. Self-collected cervicovaginal samples were obtained before treatment and at 12 months post-treatment and tested with the GeneXpert HPV assay, which detects hrHPV across five high-risk genotype channels (P1–P5). Channels P3–P5 were grouped as non-16/18/45 hrHPV types (HPV 31, 33, 35, 39, 51, 52, 56, 58, 59, 66, 68). Persistence was defined as the detection of the same channel at both time points. Differences in persistence rates were assessed using Fisher’s exact and Welch’s t -tests. Results: At 12 months post-TA, 35.6% of women were persistently hrHPV-positive. Persistence was higher among WLWH (46.0%) than women without HIV (32.0%, p = 0.01). By genotype, persistence was most common for non-16/18/45 types (37.7%), followed by HPV16 (28.9%) and HPV18/45 (18.0%). WLWH had higher persistence of non-16/18/45 types (51.8% versus 33.7% in HIV-negatives, p = 0.003), while persistence of HPV16 (35.0% versus 27.1%, p = 0.58) and HPV18/45 (26.3% versus 14.9%, p = 0.14) did not differ significantly. Conclusions: Over one-third of women had persistent hrHPV 12 months after TA, with higher rates among WLWH, primarily for non-16/18/45 genotypes. Findings highlight the need for enhanced follow-up and adjunct therapies to improve post-treatment clearance and advance cervical cancer prevention in low-resource settings.


  • Open Access

    Trying to Heal Without “Bringing Problems”: Navigating Cervical Precancer Stigma in a Phase I Clinical Trial in Western Kenya

    by Anagha Guliam, Annum Sadana, Elizabeth Opiyo, Felix Adundo, Katherine Sorgi, Erum Agha, Chemtai Mungo

    Background: Cervical cancer remains a leading cause of cancer-related deaths among women in low- and middle-income countries, particularly in sub-Saharan Africa. Sociocultural barriers including stigma significantly influence women’s decisions around screening and treatment. Objective: To explore how stigma influences women’s experiences with cervical precancer care in the context of emerging self-administered topical therapies. Design: A qualitative approach using convenience sampling. Methods: Seventeen in-depth interviews were conducted between 2024 and 2025 in Kisumu, Kenya, with women who had been diagnosed with cervical precancer. Participants were recruited to self-administer intravaginal artesunate in a Phase I clinical trial, and interviews explored their experiences. Thematic analysis was conducted using the Health Stigma and Discrimination Framework. Results: All women discussed experiences indicative of enacted, anticipated, and internalized stigmas related to partner blame, disclosure, and imagining the diagnosis as an imminent death sentence. These stigmas were driven and facilitated by poverty and limited health care access, embarrassment around sexual health, community fears of cervical cancer death, patriarchal norms, and cervical precancer’s disproportionate burden on women. Women with cervical precancer feel “marked” by medication usage, clinic visits, community expectations of a “cancer” appearance, or painful sexual intercourse. By exercising relational autonomy, women in this trial were able to navigate stigmas around sexual health and overcome the debilitating fear of death. They were ultimately able to complete the self-administered artesunate treatment course and initiate conversations in their communities to address stigmas around cervical precancer treatment. Nevertheless, stigmas caused delays to screening and treatment among some participants, while others experienced intimate partner violence or conflict during artesunate treatment. Conclusion: Stigmas around cervical precancer, artesunate usage, and abstinence requirements can deeply impact women’s social experiences, intimate partnerships, and mental health. Future trials of self-administered therapies should integrate stigma reduction strategies developed in collaboration with participants and survivors. ClinicalTrials.gov NCT06165614 , https://clinicaltrials.gov/study/NCT06165614

  • Open Access

    Feasibility of Intravaginal Artesunate as an Adjuvant HPV & Cervical Precancer Treatment Among Women Living With HIV in Kenya: Study Protocol for a Phase II Clinical Trial

    by Annum Sadana, Jackton Omoto, Katherine Sorgi, Lisa Rahangdale, Jennifer S. Smith, Mihaela Plesa, Chemtai Mungo

    Introduction: Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), who account for 90% of deaths from the disease. Human papillomavirus (HPV) is responsible for 99% of cervical cancer cases. Women living with HIV (WLWH) have a higher risk of persistent HPV infection and a greater likelihood of developing cervical cancer. Prevention of cervical cancer requires effective screening and precancer treatment programs. In LMICs, the common treatment method for cervical precancer is thermal ablation. However, for WLWH, thermal ablation is associated with high rates of persistent HPV infection following treatment, a key risk factor for precancer recurrence. Adjuvant topical treatments with cytotoxic or antiviral properties may reduce HPV persistence following ablation. Preclinical and early-phase clinical trials indicate that topical artesunate is active against HPV-associated anogenital lesions, including cervical precancer, and can induce HPV clearance. Consequently, intravaginal artesunate may improve HPV clearance following thermal ablation, although no clinical trials have investigated this. Methods: We are conducting a phase II, double-blind, randomized, placebo-controlled trial among 120 HIV seropositive women in Kenya to investigate the feasibility of self-administered intravaginal artesunate pessaries as adjuvant therapy following thermal ablation treatment for cervical precancer. The primary outcome is type-specific HPV clearance 6 months after randomization. Secondary outcomes are safety, adherence, acceptability, uptake, and retention. Participants will be enrolled at least 4 weeks after ablation and will self-administer pessaries on weeks 1, 3, and 5, with alternating drug-free weeks. Study follow-up will extend to 24 weeks after randomization. Conclusion: High rates of persistent HPV infection in WLWH is a key limitation of thermal ablation, the most accessible cervical precancer treatment in LMICs. This trial will investigate the feasibility of repurposing topical artesunate as an adjuvant therapy to improve HPV clearance following thermal ablation in WLWH. Trial Registration: ClinicalTrials.gov identifier: NCT06519994


  • Open Access

    Feasibility of intravaginal artesunate as an adjuvant HPV & cervical precancer treatment among women living with HIV in Kenya: Study protocol for a phase II clinical Trial

    by Annum Sadana, Jackton Omoto, Katherine Sorgi, Lisa Rahangdale, Jennifer Smith, Mihaela Plesa, Chemtai Mungo

    Background Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), who account for 90% of deaths from the disease. Human papillomavirus (HPV) is responsible for 99% of cervical cancer cases. Women living with HIV (WLWH) have a higher risk of persistent HPV infection and a greater likelihood of developing cervical cancer. Prevention of cervical cancer requires effective screening and precancer treatment programs. In LMICs, the common treatment method for cervical precancer is thermal ablation. However, for WLWH, thermal ablation is associated with high rates of persistent HPV infection following treatment, a key risk factor for precancer recurrence. Adjuvant topical treatments with cytotoxic or antiviral properties may reduce HPV persistence HPV following ablation. Preclinical and early-phase clinical trials indicate that topical artesunate is active against HPV-associated anogenital lesions, including cervical precancer, and can induce HPV clearance. Consequently, intravaginal artesunate may improve HPV clearance following thermal ablation, although no clinical trials have investigated this. Methods We are conducting a phase II, double-blind, randomized, placebo-controlled trial among 120 HIV seropositive women in Kenya to investigate the feasibility of self-administered intravaginal artesunate pessaries as adjuvant therapy following thermal ablation treatment for cervical precancer. The primary outcome is type-specific HPV clearance six months after randomization. Secondary outcomes are safety, adherence, acceptability, uptake, and retention. Participants will use self-administered artesunate pessaries starting at least 4 weeks following ablation, on weeks 1,3,5 with alternating drug-free weeks, with a follow-up period extending up to 24 weeks after randomization. Discussion High rates of persistent HPV infection in WLWH is a key limitation of thermal ablation, the most accessible cervical precancer treatment in LMICs. This trial will investigate the feasibility of repurposing topical artesunate as an adjuvant therapy to improve HPV clearance following thermal ablation in WLWH. Trial Registration ClinicalTrials.gov identifier: da


  • Open Access

    Phase I study on the pharmacokinetics of intravaginal, self-administered artesunate vaginal pessaries among women in Kenya

    by Chemtai Mungo, Katherine Sorgi, Brenda Misiko, Cynthia Cheserem, Lisa Rahangdale, George Githongo, Cirilus Ogollah, Jackton Omoto, Mihaela Plesa, William Zamboni

    Cervical cancer remains a significant global health issue, especially in low- and middle-income countries (LMICs), where access to prevention and treatment is limited and women are at a higher risk of cervical cancer. Artesunate, a widely available drug used to treat malaria, has shown promise in treating human papillomavirus (HPV)-associated anogenital lesions including high-grade cervical precancer, in a recent Phase I studies in the United States. Data on the pharmacokinetics of artesunate following intravaginal use, and its implications on malaria resistance, are lacking. Objectives: The primary objective of this study is to investigate the pharmacokinetics of Artesunate (AS) and its active metabolite, dihydroartemisinin (DHA) following intravaginal use at the dosing and frequency intended for cervical precancer treatment. A secondary objective is to assess safety among study participants. Methods: We are conducting a single-arm, phase I trial with a sample size of 12 female volunteers. Participants will self-administer artesunate vaginal pessaries in the study clinic daily for 5 consecutive days. Participants will have their blood drawn prior to receiving the first dose of artesunate on day one of the study and then will receive 8 blood draws on study day five, prior to artesunate administration and at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 6 hours, and 8 hours after pessary administration. Pharmacokinetic parameters of artesunate and DHA will be calculated by way of quantitative analysis of with determination of maximum concentration (Cmax), time to Cmax (Tmax), area under the serum concentration versus time curve (AUC), apparent clearance, and elimination half-life (t1/2).


  • Open Access

    Women's experiences and acceptability of self-administered, home delivered, intravaginal 5-Fluorouracil cream for cervical precancer treatment in Kenya

    by Konyin Adewumi, Aparna Kachoria, Everlyn Adoyo, Mercy Rop, Antony Owaya, Jennifer Tang, Lisa Rahangdale, Chemtai Mungo

    Background: Innovative strategies are essential to meet the World Health Organization's 90/70/90 cervical cancer elimination targets, aiming for 90% access to precancer treatment globally by 2030. In low-and middle-income countries (LMICs) where most cervical cancer cases occur, access to precancer treatment is severely limited. Scalable solutions like self-administered topical therapies can help close this gap. In a recent Phase I trial (ClinicalTrials.gov NCT05362955), we demonstrated safety and adherence to self-administered intravaginal 5% 5-Fluorouracil (5FU) cream as an adjuvant therapy for cervical precancer among women living with HIV (WLWH) in rural Kenya. To understand women's experiences with self-administered 5FU, we evaluated the acceptability of this intervention among trial participants.Methods: All 12 participants from the Phase I trial completed a structured questionnaire and in-depth semi-structured interviews in their preferred language, focusing on their experiences with 5FU self-administration, challenges faced, and overall acceptability of the intervention, including whether they would use it again or recommend it to someone who needed it. Quantitative data were analyzed using descriptive statistics. In the qualitative study, acceptability was defined as “the perception that a given treatment is agreeable, palatable, or satisfactory.” A thematic analysis was conducted using five dimensions of acceptability: content, complexity, comfort, delivery, and credibility.Results: The mean age was 43.9 years (SD 4.4), and seven (58%) had primary education or less. While some participants reported feelings of uncertainty when they started using 5FU, at the end of the study, all 12 participants strongly agreed that the cream was safe and were confident they used it correctly. Most participants (91.7%) experienced no discomfort with the vaginal applicator, and most reported using tampons overnight after 5FU use, as recommended. Qualitative findings revealed that favorable perceptions of self-administered 5FU were driven by its ease of use, the discrete nature of the treatment, and the comfort of home application. The main challenges included correctly measuring the study drug, finding a private place at home to self-administer, and the need to use condoms during treatment. Compared to their previous ablation or excision treatments, participants found 5FU to be less painful, and all would prefer a self-administered treatment instead of a procedure if it were an option.Conclusion: Self-administered intravaginal 5FU as an adjuvant treatment for cervical precancer among women living with HIV in Kenya was highly acceptable. Randomized studies of 5FU and other topical therapies in LMICs are needed to evaluate their use in closing the current precancer treatment gaps in these settings.


  • Safety and adherence to self‐administered intravaginal 5‐fluorouracil cream following cervical intraepithelial neoplasia (CIN) 2/3 treatment among HIV‐positive women in Kenya: A phase 1 clinical trial

    by Chemtai Mungo, Jackton Omoto, Cirilus Ogollah, Antony Owaya, Mercy Rop, Gershon Rota, Elizabeth A. Bukusi, Jennifer H. Tang, Lisa Rahangdale

    Objective: To determine the safety, tolerance, and adherence to self‐administered intravaginal 5% fluorouracil (5FU) cream as adjuvant therapy following cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3) treatment among women living with HIV (WLWH) in Kenya.Methods: A phase I pilot trial was performed among 12 WLWH in Kenya, aged 18–49 years between March 2023 and February 2024 (ClinicalTrial.gov NCT05362955). Participants self‐administered 2 g of 5FU intravaginally every other week for eight applications. Safety was assessed using a standardized grading scale, and adherence was evaluated using self‐report, inspection of used applicators, and weighing of the study drug.Results: The mean age and CD4 count were 43.9 years and 781 cells/mm3, respectively. Seven (58%) had an eighth‐grade education or less. All 12 reported at least one grade I adverse event (AE), one (8%) reported a grade 2 AE, no grade 3 or 4 AEs were reported. Increased vaginal discharge (n = 9, 75%) and irritation (n = 5, 42%), with a mean duration of 3.2 and 2.8 days, respectively, were the most commonly reported AEs. Provider‐observed AEs included grade 1 cervical erythema and superficial abrasions. All participants tolerated all eight 5FU doses, and 96% adherence was demonstrated.Conclusion: Self‐administered 5FU following CIN2/3 treatment among WLWH in Kisumu, Kenya, was safe, tolerable, and associated with high adherence. Randomized trials are needed to investigate whether adjuvant 5FU can improve treatment outcomes or serve as primary cervical precancer treatment in sub‐Saharan Africa. A self‐administered therapy may be transformative in increasing access to treatment and, hence, secondary prevention of cervical cancer.


  • Open Access

    “It was not normal, and I had to find a doctor and tell him.” Kenyan Women's Response to Cervical Cancer Symptoms

    by Rahma Mkuu, Charity Hungu, Francis Makokha, Idethia Harvey, Benda Kithaka, Sharon Mweni, Chemtai Mungo, Daniela Rivero-Mendoza, Jaclyn M. Hall, Joystacy Mutegi, et al.

    This study aimed to characterize the cervical cancer diagnosis experience of Kenyan women undergoing treatment for cervical cancer. We analyzed qualitative interviews with 29 women living in rural Kenya who were currently undergoing cervical cancer treatment at Machakos Cancer Care and Research Centre at Machakos Level 5 Referral Hospital in eastern Kenya. Semistructured qualitative interviews were conducted in Kiswahili and English and then de-identified and translated to English during transcription. The main themes generated were identified through an inductive approach to determine how women experienced cervical cancer symptoms and their process of navigating healthcare. Three themes emerged from the qualitative interviews: (1) delaying seeking care, (2) misinterpreting or misdiagnoses, and (3) grappling with the costly diagnosis process. Women misattributed early signs of cervical cancer to benign conditions. Women sought care only after experiencing severe symptoms. When they sought care, women reported facing lengthy and costly screening processes before receiving a cervical cancer diagnosis. There is a need to educate women on the early symptoms of cervical cancer and to increase the institutional capacity and availability of cervical cancer screening resources in healthcare facilities.


  • Open Access

    Assessing generalizability of an AI-based visual test for cervical cancer screening

    by Syed Rakin Ahmed, Didem Egemen, Brian Befano, Ana Cecilia Rodriguez, Jose Jeronimo, Kanan Desai, Carolina Teran, Karla Alfaro, Joel Fokom-Domgue, Kittipat Charoenkwan, et al.

    A number of challenges hinder artificial intelligence (AI) models from effective clinical translation. Foremost among these challenges is the lack of generalizability, which is defined as the ability of a model to perform well on datasets that have different characteristics from the training data. We recently investigated the development of an AI pipeline on digital images of the cervix, utilizing a multi-heterogeneous dataset of 9,462 women (17,013 images) and a multi-stage model selection and optimization approach, to generate a diagnostic classifier able to classify images of the cervix into “normal”, “indeterminate” and “precancer/cancer” (denoted as “precancer+”) categories. In this work, we investigate the performance of this multiclass classifier on external data not utilized in training and internal validation, to assess the generalizability of the classifier when moving to new settings. We assessed both the classification performance and repeatability of our classifier model across the two axes of heterogeneity present in our dataset: image capture device and geography, utilizing both out-of-the-box inference and retraining with external data. Our results demonstrate that device-level heterogeneity affects our model performance more than geography-level heterogeneity. Classification performance of our model is strong on images from a new geography without retraining, while incremental retraining with inclusion of images from a new device progressively improves classification performance on that device up to a point of saturation. Repeatability of our model is relatively unaffected by data heterogeneity and remains strong throughout. Our work supports the need for optimized retraining approaches that address data heterogeneity (e.g., when moving to a new device) to facilitate effective use of AI models in new settings.


  • Open Access

    Women’s experiences and acceptability of self-administered, home delivered, intravaginal 5-Fluorouracil cream for cervical precancer treatment in Kenya

    by Konyin Adewumi, Aparna Ghosh Kachoria, Everlyn Adoyo, Mercy Rop, Antony Owaya, Jennifer H Tang, Lisa Rahangdale, Chemtai Mungo

    BACKGROUND Innovative strategies are essential to meet the World Health Organization’s 90/70/90 cervical cancer elimination targets, aiming for 90% access to precancer treatment globally by 2030. In low-and middle-income countries (LMICs) where most cervical cancer cases occur, access to precancer treatment is severely limited. Scalable solutions like self-administered topical therapies can help close this gap. In a recent Phase I trial (ClinicalTrials.gov NCT05362955), we demonstrated safety and adherence to self-administered intravaginal 5% 5-Fluorouracil (5FU) cream as an adjuvant therapy for cervical precancer among women living with HIV (WLWH) in rural Kenya. To understand women’s experiences with self-administered 5FU, we evaluated the acceptability of this intervention among trial participants. METHODS All 12 participants from the Phase I trial completed a structured questionnaire and in-depth semi-structured interviews in their preferred language, focusing on their experiences with 5FU self-administration, challenges faced, and overall acceptability of the intervention, including whether they would use it again or recommend it to someone who needed it. Quantitative data were analyzed using descriptive statistics. In the qualitative study, acceptability was defined as "the perception that a given treatment is agreeable, palatable, or satisfactory." A thematic analysis was conducted using five dimensions of acceptability: content, complexity, comfort, delivery, and credibility. RESULTS The mean age was 43.9 years (SD 4.4), and 7 (58%) had primary education or less. While some participants reported feelings of uncertainty when they started using 5FU, at the end of the study, all twelve participants strongly agreed that the cream was safe and were confident they used it correctly. Most participants (91.7%) experienced no discomfort with the vaginal applicator, and most reported using tampons overnight after 5FU use, as recommended. Qualitative findings revealed that favorable perceptions of self-administered 5FU were driven by its ease of use, the discrete nature of the treatment, and the comfort of home application. The main challenges included correctly measuring the study drug, finding a private place at home to self-administer, and the need to use condoms during treatment. Compared to their previous ablation or excision treatments, participants found 5FU to be less painful, and all would prefer a self-administered treatment instead of a procedure if it were an option. CONCLUSION Self-administered intravaginal 5FU as an adjuvant treatment for cervical precancer among women living with HIV in Kenya was highly acceptable. Randomized studies of 5FU and other topical therapies in LMICs are needed to evaluate their use in closing the current precancer treatment gaps in these settings.